Literature DB >> 31682306

Clinical characteristics and prognostic factors of malignant tumors involving pterygopalatine fossa.

Hyun-Jae Woo1,2, Peter H Hwang2, Michael J Kaplan2, Garret Choby2,3.   

Abstract

BACKGROUND: To identify the clinical characteristics and prognostic factors of malignancies involving the pterygopalatine fossa (PPF).
METHODS: Fifty-seven patients who underwent curative surgery for malignant tumor involving PPF were reviewed.
RESULTS: The rates for three-year local control (LC), five-year disease-free survival (DFS) and five-year overall survival (OS) were 55.4%, 34.5%, and 52.7%, respectively. Perineural invasion (PNI) of the maxillary nerve with facial numbness (symptomatic V2 PNI) (P = .04) and cranial involvement (P = .03) were predictors for poor OS. Symptomatic V2 PNI was also a significant predictor for poor LC (P = .05) and DFS (P = .03). Within the subgroup analysis of patients with pathologically confirmed V2 PNI, asymptomatic V2 PNI patients had significantly better LC (71.2% vs 31.8%, P = .05) and DFS (43.8% vs 17.3%, P = .05) compared to symptomatic patients.
CONCLUSION: Malignant tumors involving the PPF have diverse pathologies and a poor prognosis. Symptomatic V2 PNI may be an independent poor prognostic factor.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  malignant tumor; maxillary nerve; perineural invasion; prognosis; pterygopalatine fossa

Mesh:

Year:  2019        PMID: 31682306     DOI: 10.1002/hed.26000

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

Review 1.  Three-hundred and sixty degrees of surgical approaches to the maxillary sinus.

Authors:  Natália C Rezende; Carlos D Pinheiro-Neto; Luciano C P C Leonel; Jamie J Van Gompel; Maria Peris-Celda; Garret Choby
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2022-03-22

2.  Myxofibrosarcoma metastasis to the pterygopalatine fossa: A case report.

Authors:  Haya Deeb; Afaf Ahmad; Areej AlAssaf
Journal:  Ann Med Surg (Lond)       Date:  2020-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.